<DOC>
	<DOCNO>NCT00994266</DOCNO>
	<brief_summary>The purpose study assess efficacy Diamel ( dietary supplement ) administration treatment patient type 2 diabetes receive insulin therapy . The duration double-blind placebo control phase 3 clinical trial 24 week . The estimated number patient recruit randomized study 116 . Daily insulin requirement , blood glucose ( fast post-prandial ) concentration , glycosylated hemoglobin ( HbA1c ) , triglycerides cholesterol assess begin 24 week treatment .</brief_summary>
	<brief_title>Diamel Treatment Type 2 Diabetic Patients Receiving Insulin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 2 diabetes insulin therapy regimen two daily dos . Signed informed consent . Type 1 diabetes . Type 2 diabetes glibenclamide treatment . Nephropathy liver condition diagnose clinical and/or biochemical examination . Sepsis . Pregnancy . HbA1c value great 10 % .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Diamel</keyword>
	<keyword>Dietary supplement</keyword>
</DOC>